Journal article
Molecular imaging of T cell co-regulator factor B7-H3 with 89Zr-DS-5573a
IJG Burvenich, S Parakh, FT Lee, N Guo, Z Liu, HK Gan, A Rigopoulos, GJ O'Keefe, SJ Gong, YW Goh, H Tochon-Danguy, FE Scott, M Kotsuma, K Hirotani, G Senaldi, AM Scott
Theranostics | IVYSPRING INT PUBL | Published : 2018
DOI: 10.7150/thno.25575
Abstract
B7-H3 is a transmembrane protein widely expressed in a variety of cancers and has been shown to play a role in anti-tumor immunity. This study aims to develop a molecular imaging probe to identify B7-H3 expression in tumors and to develop 89Zr-DS-5573a as a theranostic that could aid patient selection in clinical Phase I studies. Methods: The anti-B7-H3 humanised monoclonal antibody DS-5573a was labeled with zirconium-89 (89Zr-), and assessed for radiochemical purity, immunoreactivity (Lindmo analysis), antigen binding affinity (Scatchard analysis), and serum stability in vitro. In vivo biodistribution and imaging studies were performed with positron emission tomography and magnetic resonanc..
View full abstractGrants
Awarded by EA Pharma Co., Ltd.
Funding Acknowledgements
This work was supported by funding from Daiichi-Sankyo Co., Ltd. We acknowledge the Australian Cancer Research Foundation for providing funds to purchase the PET/MRI and nanoSPECT/CT imaging equipment. This research was also undertaken using the Solid Target Laboratory, an ANSTO-Austin-LICR Partnership. The support of the Operational Infrastructure Support Program of the Victorian State Government; SP (LaTrobe University PhD Scholarship) and AMS (NHRMC Practitioner Fellowship APP1084178) is acknowledged.